Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years

NCT01995175 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01995175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01995175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years
Lead sponsor
GlaxoSmithKline
Phase
Not applicable
Overall status
Completed
Start date
December 12, 2013
Completion date
November 3, 2021
Enrollment
2,409 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus